Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inquiry

Fertility and Early Embryo Development Toxicity Evaluation

Fertility and early embryo development (FEED) toxicity evaluation is the first segment of developmental and reproductive toxicology evaluation. Our company has many years of experience in rare disease drug safety evaluation services and has the resources and capabilities to provide clients with custom study designs. Our safety evaluation experts provide unparalleled fertility and early embryotoxicity evaluation services.

Introduction to Fertility and Early Embryo Development Toxicity Evaluation

Fertility and early embryonic development (FEED) toxicity evaluation refers to the evaluation of effects on mating, estrous cyclicity, spermatogenesis, and ability to produce a viable implant, thereby evaluating their reproductive toxicity to animals and providing a reference for related research. In fertility and early embryonic development toxicity evaluation, body weight and food intake should be paid special attention. Abnormalities in body weight and food intake will directly affect subsequent mating behavior.

Toxicity Symptoms of Fertility and Early Embryo Development

The toxicity of drugs can interfere with any aspect of reproductive development and cause damage. It may have indirect toxic effects through the endocrine system, or it may regulate the endocrine system through the nervous system and act on the reproductive development process through the hypothalamus. Drug toxicity can cause the following common symptoms of fertility and early embryonic development:

  • Sexual dysfunction
  • Abnormal ovulation
  • Menstrual disorders
  • Ovarian atrophy
  • Fewer pregnancies
  • Embryonic death
  • Infertility
  • Testicular atrophy
  • Low sperm count
1-3-2-3-1 Fertility and Early Embryo Development Toxicity Evaluation-1 Fig.1 Schematic representation of the processes before and during embryonic development. (Saint-Dizier, M., et al., 2019)

Our Services

With many years of experience, our company provides clients with reasonable fertility and early embryonic development toxicity evaluation protocols. Our animal platform provides mice, rabbits, rats, and other experimental animals and combine the protocols to develop different administration routes, including dietary, dermal, gavage, vaginal, intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, etc. Combined with our bioanalytical platform, we provide clients with a one-stop evaluation service.

Female FEED Evaluation Male Fertility Evaluation Histopathological Evaluation
  • Estrous cycles
  • Tubal transport
  • Implantation and embryonic development
  • Libido evaluation
  • Sperm evaluation (concentration, motility, morphology)
  • Reproductive and endocrine tissues evaluation
  • Primordial and small growing follicles evaluation
  • Sperm morphology and staging evaluation

Our Advantages

  • Cutting-edge technology and equipment
  • Professional technical support
  • Stringent quality control and testing
  • Careful design and transparent operation process
  • Innovative and flexible solutions
  • Reliable and trusted partner

Project Workflow

1-3-2-3-1 Fertility and Early Embryo Development Toxicity Evaluation-5

With a research team with extensive expertise in drug safety evaluation, our company is confident to provide clients with fertility and early embryo development toxicity evaluation services for rare diseases. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more information.

Reference

  • Saint-Dizier, M., et al. "Composing the early embryonic microenvironment: physiology and regulation of oviductal secretions." International journal of molecular sciences 21.1 (2019): 223.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.